MCID: THY121
MIFTS: 67

Thyroid Gland Anaplastic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thyroid Gland Anaplastic Carcinoma

MalaCards integrated aliases for Thyroid Gland Anaplastic Carcinoma:

Name: Thyroid Gland Anaplastic Carcinoma 11 14
Anaplastic Thyroid Carcinoma 11 19 58 71
Thyroid Cancer, Anaplastic 19 5
Anaplastic Thyroid Cancer 19 75
Thyroid Carcinoma, Anaplastic 19
Thyroid Carcinoma Anaplastic 53

Characteristics:


Prevelance:

Anaplastic Thyroid Carcinoma: 1-9/1000000 (Europe, Europe) 58

Age Of Onset:

Anaplastic Thyroid Carcinoma: Adult,Elderly 58

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 11 DOID:0080522
NCIt 49 C3878
MESH via Orphanet 44 C536910
ICD10 via Orphanet 32 C73
UMLS via Orphanet 72 C0238461
Orphanet 58 ORPHA142
UMLS 71 C0238461

Summaries for Thyroid Gland Anaplastic Carcinoma

GARD: 19 Anaplastic thyroid cancer (ATC) accounts for less than 2% of all thyroid cancers and is the most aggressive type of thyroid cancer. Women are more likely to be affected than men. ATC generally occurs in individuals with a history of goiter or thyroid cancer. A history of head and neck radiation or exposure to radioactive materials may also increase the risk for ATC. Patients with ATC generally present with a rapidly-growing neck mass which may cause trouble swallowing (dysphagia), coughing, neck pain, and trouble breathing (dyspnea). Metastasis is present in more than half of individuals at the time of diagnosis. Patients with metastases may also present with bone pain, lymph node enlargement, weakness, and neurological deficits.

MalaCards based summary: Thyroid Gland Anaplastic Carcinoma, also known as anaplastic thyroid carcinoma, is related to thyroid carcinoma and thyroid cancer, nonmedullary, 1, and has symptoms including dyspnea and hoarseness. An important gene associated with Thyroid Gland Anaplastic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signal Transduction and Malignant pleural mesothelioma. The drugs Levoleucovorin and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and bone, and related phenotypes are anaplastic thyroid carcinoma and broad neck

Orphanet: 58 A disorder that represents the ultimate dedifferentiation step of thyroid tumorigenesis and is one of the most severe cancers in humans.

Disease Ontology: 11 A thyroid gland carcinoma that is composed of undifferentiated cells.

Wikipedia: 75 Anaplastic thyroid cancer (ATC), also known as anaplastic thyroid carcinoma, is an aggressive form of... more...

Related Diseases for Thyroid Gland Anaplastic Carcinoma

Diseases related to Thyroid Gland Anaplastic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 512)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma 32.9 TG RET BRAF
2 thyroid cancer, nonmedullary, 1 32.1 TP53 NKX2-1 BRAF
3 differentiated thyroid carcinoma 32.0 RET PAX8 NKX2-1 BRAF
4 thyroid tumor 31.8 RET PTEN PIK3CA BRAF
5 papillary carcinoma 31.6 TSHR TPO TG RET PAX8 NKX2-1
6 graves disease 1 31.6 TSHR TPO TG CALCA
7 thyroiditis 31.6 TSHR TPO TG RET CALCA
8 thyroid cancer, nonmedullary, 2 31.5 TSHR TG PTEN PAX8 CALCA BRAF
9 thyroid gland follicular carcinoma 31.3 TSHR TPO TP53 TG RET PTEN
10 multinodular goiter 31.3 TSHR TPO TG RET PTEN PAX8
11 hypothyroidism 31.2 TSHR TPO TG RET PAX8 NKX2-1
12 thyroid lymphoma 31.2 TPO TG RET CALCA
13 hypothyroidism, congenital, nongoitrous, 1 31.2 TSHR TG PAX8
14 thyroid carcinoma, familial medullary 31.2 TG RET NKX2-1 CALCA BRAF
15 endocrine gland cancer 31.2 RET MIR34C MIR30A MIR18A MIR17
16 nodular goiter 31.1 TSHR TPO TG RET CALCA BRAF
17 graves' disease 31.1 TSHR TPO TG PAX8
18 hypothyroidism, congenital, nongoitrous, 2 31.1 TSHR TG PAX8 NKX2-1
19 subacute thyroiditis 31.1 TSHR TPO TG
20 adenoma 31.1 TSHR TP53 TG RET PIK3CA CTNNB1
21 thyroid gland medullary carcinoma 31.1 TG RET PAX8 NKX2-1 CALCA
22 endemic goiter 31.1 TSHR TPO TG PAX8 CALCA
23 hyperthyroidism 31.0 TSHR TPO TG CALCA
24 hashimoto thyroiditis 31.0 TSHR TPO TG RET CALCA BRAF
25 squamous cell carcinoma 31.0 TP53 PTEN PIK3CA NKX2-1 CTNNB1 CDH1
26 follicular adenoma 31.0 TSHR TPO TG RET PTEN PAX8
27 melanoma 31.0 TP53 PTEN PIK3CA MIR34C MIR19A MIR17
28 nontoxic goiter 30.9 TSHR TPO TG CALCA
29 substernal goiter 30.9 TG RET CALCA
30 hypoparathyroidism 30.9 TPO RET CALCA
31 gastrointestinal stromal tumor 30.9 TP53 RET PTEN PIK3CA CTNNB1 BRAF
32 lung cancer susceptibility 3 30.8 TP53 PIK3CA NKX2-1 MIR30A MIR17 CTNNB1
33 goiter 30.8 TSHR TPO TG RET PAX8 NKX2-1
34 squamous cell carcinoma, head and neck 30.8 TP53 PTEN PIK3CA MIR30A MIR19A MIR18A
35 endometrial cancer 30.8 TP53 PTEN PIK3CA MIR30A CTNNB1 CDH1
36 papillary thyroid microcarcinoma 30.7 TG NKX2-1 CALCA BRAF
37 acute thyroiditis 30.7 TPO TG CALCA
38 papillary adenocarcinoma 30.7 TP53 TG PAX8 NKX2-1 MIR30A
39 lymphatic system disease 30.7 TP53 MIR34C MIR30A MIR18A MIR17
40 bilateral breast cancer 30.7 TP53 PTEN CDH1
41 lung cancer 30.7 TP53 RET PTEN PIK3CA NKX2-1 MIR34C
42 lipomatosis, multiple 30.7 TP53 PTEN PIK3CA
43 li-fraumeni syndrome 30.7 TP53 PTEN PIK3CA CTNNB1 CDH1
44 hematologic cancer 30.7 MIR34C MIR30A MIR19A MIR18A MIR17
45 cowden syndrome 30.7 TP53 RET PTEN PIK3CA MIR19A CTNNB1
46 mixed cell type cancer 30.7 TP53 PTEN PIK3CA PAX8 CTNNB1 CDH1
47 mucoepidermoid carcinoma 30.7 TG CDH1 CALCA
48 mesothelioma, malignant 30.7 NKX2-1 MIR17 CTNNB1 CDH1
49 leukemia, chronic myeloid 30.7 TP53 PTEN MIR30A MIR19A MIR18A MIR17
50 inherited cancer-predisposing syndrome 30.6 TP53 RET PTEN CDH1

Graphical network of the top 20 diseases related to Thyroid Gland Anaplastic Carcinoma:



Diseases related to Thyroid Gland Anaplastic Carcinoma

Symptoms & Phenotypes for Thyroid Gland Anaplastic Carcinoma

Human phenotypes related to Thyroid Gland Anaplastic Carcinoma:

58 30 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anaplastic thyroid carcinoma 58 30 Obligate (100%) Obligate (100%)
HP:0011779
2 broad neck 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000475
3 hoarse voice 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001609
4 nodular goiter 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0005994
5 dysphagia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002015
6 vocal cord paralysis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001605
7 neoplasm of the lung 58 30 Frequent (33%) Frequent (79-30%)
HP:0100526
8 respiratory distress 58 30 Frequent (33%) Frequent (79-30%)
HP:0002098
9 lymphadenopathy 58 30 Frequent (33%) Frequent (79-30%)
HP:0002716
10 upper airway obstruction 58 30 Frequent (33%) Frequent (79-30%)
HP:0002781
11 pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0012531
12 laryngotracheal stenosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0004894
13 dysphonia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001618
14 hemoptysis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002105
15 cough 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012735
16 weight loss 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001824
17 stridor 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010307
18 neoplasm of the skeletal system 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010622
19 abnormal skeletal muscle morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011805
20 tracheoesophageal fistula 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002575
21 malignant neoplasm of the central nervous system 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100836
22 dyspnea 58 Occasional (29-5%)
23 goiter 58 Very frequent (99-80%)

UMLS symptoms related to Thyroid Gland Anaplastic Carcinoma:


dyspnea; hoarseness

MGI Mouse Phenotypes related to Thyroid Gland Anaplastic Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 10.2 ADGRE5 BRAF CALCA CDH1 CTNNB1 MIR18A
2 neoplasm MP:0002006 10.18 BRAF CALCA CDH1 CTNNB1 NKX2-1 PIK3CA
3 endocrine/exocrine gland MP:0005379 10.1 BRAF CDH1 CTNNB1 NKX2-1 PAX8 PIK3CA
4 limbs/digits/tail MP:0005371 10.06 BRAF CTNNB1 PAX8 PTEN RET TG
5 no phenotypic analysis MP:0003012 10.03 ADGRE5 CDH1 CTNNB1 NKX2-1 PAX8 PIK3CA
6 hearing/vestibular/ear MP:0005377 9.97 BRAF CALCA CTNNB1 PAX8 TG TP53
7 embryo MP:0005380 9.91 BRAF CALCA CDH1 CTNNB1 PAX8 PIK3CA
8 digestive/alimentary MP:0005381 9.81 BRAF CDH1 CTNNB1 NKX2-1 PIK3CA PTEN
9 reproductive system MP:0005389 9.7 BRAF CDH1 CTNNB1 NKX2-1 PAX8 PIK3CA
10 skeleton MP:0005390 9.36 BRAF CALCA CTNNB1 NKX2-1 PAX8 PIK3CA

Drugs & Therapeutics for Thyroid Gland Anaplastic Carcinoma

Drugs for Thyroid Gland Anaplastic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
3
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
4
Fluorouracil Approved Phase 2 51-21-8 3385
5
Hydroxyurea Approved Phase 2 127-07-1 3657
6
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
7
Vemurafenib Approved Phase 2 918504-65-1 42611257
8
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
9
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
10
Aldesleukin Approved Phase 2 110942-02-4
11
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
12
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
13
Nivolumab Approved Phase 2 946414-94-4
14
Ipilimumab Approved Phase 2 477202-00-9
15
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
16
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
17
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
18
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
19
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
20
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
21
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
22
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 5702198 441203
23
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Spartalizumab Investigational Phase 1, Phase 2 1935694-88-4
26
Efatutazone Investigational Phase 1, Phase 2 223132-37-4 9832447
27 Folic Acid Antagonists Phase 2
28 Folate Phase 2
29 Vitamin B9 Phase 2
30 Vitamin B Complex Phase 2
31 Antimetabolites Phase 2
32 Immunoglobulins, Intravenous Phase 2
33 Immunoglobulins Phase 2
34 Immunoglobulin G Phase 2
35 Antibodies, Monoclonal Phase 2
36 Antibodies Phase 2
37 Immunologic Factors Phase 2
38 Endothelial Growth Factors Phase 2
39 Mitogens Phase 2
40 Antibodies, Bispecific Phase 2
41 Alkylating Agents Phase 2
42 Antiviral Agents Phase 2
43 Anti-Retroviral Agents Phase 2
44 Antineoplastic Agents, Alkylating Phase 2
45 Anti-Infective Agents Phase 2
46 Interleukin-2 Phase 2
47 Anti-HIV Agents Phase 2
48 Analgesics, Non-Narcotic Phase 2
49 Analgesics Phase 2
50 Immunosuppressive Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT] Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2) Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
3 Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Unknown status NCT03565536 Phase 2 Nexavar
4 Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
5 A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
6 A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer Completed NCT00625846 Phase 2 Pazopanib Hydrochloride
7 A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer Completed NCT01236547 Phase 2 Paclitaxel;Pazopanib Hydrochloride
8 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE) Completed NCT02726503 Phase 2 Lenvatinib
9 Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer Completed NCT03211117 Phase 2 Docetaxel;Doxorubicin Hydrochloride
10 A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer Completed NCT00004089 Phase 2 fluorouracil;hydroxyurea;paclitaxel
11 A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed NCT01240590 Phase 1, Phase 2 Crolibulin;Cisplatin
12 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer Completed NCT00654238 Phase 2 sorafenib
13 Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer Completed NCT02688608 Phase 2 Pembrolizumab
14 Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies Completed NCT02404441 Phase 1, Phase 2
15 Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid Completed NCT00060242 Phase 2 fosbretabulin disodium
16 Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting NCT03181100 Phase 2 Atezolizumab;Cobimetinib;Nab-paclitaxel;Paclitaxel;Vemurafenib
17 Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Recruiting NCT04171622 Phase 2 Lenvatinib
18 A Phase II, Multicenter Study of XmAb20717 in Patients With Metastatic Anaplastic Thyroid Cancer With an Exploratory Cohort in Aggressive Hurthle Cell Thyroid Cancer Recruiting NCT05453799 Phase 2 Vudalimab
19 Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO) Recruiting NCT04739566 Phase 2 Dabrafenib;Trametinib
20 Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer Recruiting NCT04675710 Phase 2 Dabrafenib;Trametinib
21 Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers Recruiting NCT04759911 Phase 2 Selpercatinib
22 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine
23 A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib Recruiting NCT04238624 Phase 2 Dabrafenib;Trametinib
24 An Open Label, Multicenter Phase Ib/II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation Recruiting NCT05102292 Phase 1, Phase 2 HLX208
25 An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Recruiting NCT04579757 Phase 1, Phase 2 Surufatinib and Tislelizumab _ Part 1;Surufatinib and Tislelizumab _ Part 2
26 Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study Recruiting NCT04400474 Phase 2 Cabozantinib 40 mg
27 Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Recruiting NCT05119296 Phase 2 Pembrolizumab (Keytruda)
28 A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma Active, not recruiting NCT04592484 Phase 1, Phase 2
29 A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer Active, not recruiting NCT02244463 Phase 2 MLN0128
30 A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer Active, not recruiting NCT03246958 Phase 2 Nivolumab;Ipilimumab
31 A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer Active, not recruiting NCT02152137 Phase 2 efatutazone;paclitaxel
32 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Active, not recruiting NCT04552769 Phase 2 Abemaciclib
33 A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With Anaplastic Thyroid Cancer Not yet recruiting NCT04574817 Phase 2 HX008
34 Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer Suspended NCT04731740 Phase 2 Lenvatinib;Chemotherapy
35 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Terminated NCT02657369 Phase 2 Lenvatinib 24 mg
36 Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer Terminated NCT00804830 Phase 2 Bevacizumab
37 Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation] Terminated NCT00077103 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;fosbretabulin disodium
38 Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer Terminated NCT00115739 Phase 2 Imatinib
39 A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer Terminated NCT00603941 Phase 1, Phase 2 CS-7017;Paclitaxel
40 Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid Terminated NCT00126568 Phase 2 sorafenib tosylate
41 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
42 A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer Terminated NCT03002623 Phase 2 CUDC-907
43 Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Withdrawn NCT02289144 Phase 2 Ceritinib
44 A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer Completed NCT03122496 Phase 1 durvalumab;tremelimumab
45 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
46 A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer Recruiting NCT04420754 Phase 1
47 A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer Suspended NCT03975231 Phase 1 Dabrafenib;Trametinib
48 A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers Withdrawn NCT02516774 Phase 1 Adalimumab
49 A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer Completed NCT00280852
50 Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients Completed NCT02862470

Search NIH Clinical Center for Thyroid Gland Anaplastic Carcinoma

Genetic Tests for Thyroid Gland Anaplastic Carcinoma

Anatomical Context for Thyroid Gland Anaplastic Carcinoma

Organs/tissues related to Thyroid Gland Anaplastic Carcinoma:

MalaCards : Thyroid, Lymph Node, Bone, Lung, Skeletal Muscle, Endothelial, Breast

Publications for Thyroid Gland Anaplastic Carcinoma

Articles related to Thyroid Gland Anaplastic Carcinoma:

(show top 50) (show all 2322)
# Title Authors PMID Year
1
Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. 62 46
18429962 2008
2
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. 5
8423216 1993
3
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. 5
1565144 1992
4
Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. 46
20198305 2010
5
Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model. 53 62
19727716 2010
6
Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells. 53 62
19825993 2009
7
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. 53 62
19500021 2009
8
R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. 53 62
19230027 2009
9
Anaplastic thyroid cancer: prevalence, diagnosis and treatment. 53 62
18923370 2008
10
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. 53 62
18831514 2008
11
Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. 53 62
18509005 2008
12
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. 53 62
18502332 2008
13
HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. 53 62
18356165 2008
14
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. 53 62
18458053 2008
15
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. 53 62
18000091 2008
16
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. 53 62
17878251 2007
17
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. 46
17563749 2007
18
[Gene abnormalities in thyroid cancer]. 53 62
18018556 2007
19
[Molecular mechanism of thyroid carcinogenesis]. 53 62
18018555 2007
20
Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines. 53 62
17671725 2007
21
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. 53 62
17327374 2007
22
A conditionally replicative, Wnt/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. 53 62
17218945 2007
23
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. 53 62
16777971 2006
24
Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. 53 62
16899627 2006
25
Antisense p53 decreases production of VEGF in follicular thyroid cancer cells. 53 62
16943578 2006
26
Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. 53 62
16551737 2006
27
Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. 53 62
16647341 2006
28
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. 53 62
16331265 2006
29
BRAF is a therapeutic target in aggressive thyroid carcinoma. 53 62
16533790 2006
30
Redox control of manumycin A-induced apoptosis in anaplastic thyroid cancer cells: involvement of the xenobiotic apoptotic pathway. 53 62
16410725 2006
31
Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. 53 62
16263821 2006
32
Differential effects of TGF-beta1 on telomerase activity in thyroid carcinoma cell lines. 53 62
16288728 2005
33
Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray. 53 62
16264365 2005
34
Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. 53 62
16278386 2005
35
S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. 53 62
16265347 2005
36
Mutation of the PIK3CA gene in anaplastic thyroid cancer. 53 62
16288007 2005
37
Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. 53 62
16030158 2005
38
RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. 53 62
15980887 2005
39
Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. 53 62
16093430 2005
40
Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. 53 62
16029487 2005
41
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. 53 62
15880523 2005
42
Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. 53 62
15650765 2005
43
Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. 53 62
15785737 2005
44
Advances in the management of thyroid cancer. 53 62
17462286 2005
45
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. 53 62
15195111 2004
46
Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. 53 62
14976143 2004
47
Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. 53 62
14654945 2004
48
[Genetic causes of the thyroid carcinomas]. 53 62
15584614 2004
49
Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. 53 62
12915687 2003
50
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. 53 62
12843138 2003

Variations for Thyroid Gland Anaplastic Carcinoma

ClinVar genetic disease variations for Thyroid Gland Anaplastic Carcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic
12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802

Cosmic variations for Thyroid Gland Anaplastic Carcinoma:

8 (show top 50) (show all 5257)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90416635 ZNF703 thyroid,NS,carcinoma,anaplastic carcinoma c.1232C>T p.A411V 8:37698133-37698133 17
2 COSM84513642 ZNF276 thyroid,NS,carcinoma,anaplastic carcinoma c.*2596A>T p.? 16:89740842-89740842 17
3 COSM101980343 XPO1 thyroid,NS,carcinoma,anaplastic carcinoma c.1353A>G p.I451M 2:61492946-61492946 17
4 COSM104240109 XPO1 thyroid,NS,carcinoma,anaplastic carcinoma c.1353A>G p.I451M 2:61492946-61492946 17
5 COSM104886876 XPO1 thyroid,NS,carcinoma,anaplastic carcinoma c.1353A>G p.I451M 2:61492946-61492946 17
6 COSM90659403 VHL thyroid,NS,carcinoma,anaplastic carcinoma c.289C>T p.P97S 3:10142136-10142136 17
7 COSM88298168 VHL thyroid,NS,carcinoma,anaplastic carcinoma c.289C>T p.P97S 3:10142136-10142136 17
8 COSM116191954 UQCC5 thyroid,NS,carcinoma,anaplastic carcinoma c.152-14856G>C p.? 3:52564162-52564162 17
9 COSM116186743 UQCC5 thyroid,NS,carcinoma,anaplastic carcinoma c.152-17231G>C p.? 3:52561787-52561787 17
10 COSM102449047 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.28G>C p.E10Q 21:43095696-43095696 17
11 COSM99372056 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.247G>C p.E83Q 21:43095696-43095696 17
12 COSM112017925 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.78G>A p.M26I 21:43095489-43095489 17
13 COSM99368161 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.297G>A p.M99I 21:43095489-43095489 17
14 COSM112020403 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.28G>C p.E10Q 21:43095696-43095696 17
15 COSM85196814 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.247G>C p.E83Q 21:43095696-43095696 17
16 COSM85193419 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.297G>A p.M99I 21:43095489-43095489 17
17 COSM102445292 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.78G>A p.M26I 21:43095489-43095489 17
18 COSM86824282 TYRO3 thyroid,NS,carcinoma,anaplastic carcinoma c.2194C>T p.P732S 15:41573727-41573727 17
19 COSM135709676 TYRO3 thyroid,NS,carcinoma,anaplastic carcinoma c.2059C>T p.P687S 15:41573727-41573727 17
20 COSM131092631 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1672G>A p.V558M 14:81143730-81143730 17
21 COSM85466293 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1703T>C p.I568T 14:81143761-81143761 17
22 COSM85466972 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1789G>C p.V597L 14:81143847-81143847 17
23 COSM85466282 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1514G>A p.S505N 14:81143572-81143572 17
24 COSM131089965 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1911G>T p.M637I 14:81143969-81143969 17
25 COSM85472824 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1911G>T p.M637I 14:81143969-81143969 17
26 COSM85469801 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.842G>C p.S281T 14:81139828-81139828 17
27 COSM131087195 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.842G>C p.S281T 14:81139828-81139828 17
28 COSM85475366 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1672G>A p.V558M 14:81143730-81143730 17
29 COSM131089960 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1898A>C p.D633A 14:81143956-81143956 17
30 COSM131083598 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1703T>C p.I568T 14:81143761-81143761 17
31 COSM131084149 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1789G>C p.V597L 14:81143847-81143847 17
32 COSM85472813 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1898A>C p.D633A 14:81143956-81143956 17
33 COSM131083592 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1514G>A p.S505N 14:81143572-81143572 17
34 COSM101185486 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.1292A>G p.Y431C 16:2063049-2063049 17
35 COSM151512883 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.5038G>A p.D1680N 16:2088092-2088092 17
36 COSM150313015 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.4912G>A p.D1638N 16:2088092-2088092 17
37 COSM147690582 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.4984G>A p.D1662N 16:2088092-2088092 17
38 COSM151380590 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.793G>T p.G265C 16:2057123-2057123 17
39 COSM110102153 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.4804G>A p.D1602N 16:2088092-2088092 17
40 COSM147690543 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 17
41 COSM149800713 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 17
42 COSM151746971 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 17
43 COSM110124471 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.682G>T p.G228C 16:2057123-2057123 17
44 COSM149823983 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.793G>T p.G265C 16:2057123-2057123 17
45 COSM150574934 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.4906G>A p.D1636N 16:2088092-2088092 17
46 COSM90402476 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.5044G>A p.D1682N 16:2088092-2088092 17
47 COSM151370140 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 17
48 COSM87033564 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.1439A>G p.Y480C 16:2063049-2063049 17
49 COSM87027114 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 17
50 COSM149807155 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.1439A>G p.Y480C 16:2063049-2063049 17

Copy number variations for Thyroid Gland Anaplastic Carcinoma from CNVD:

6 (show all 18)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 18562 1 146514610 148102224 Gain Anaplastic thyroid cancer
2 57418 11 63321142 66212707 Gain CCND1 Anaplastic thyroid cancer
3 68082 12 47384342 48639263 Gain Anaplastic thyroid cancer
4 78984 13 61113549 63481793 Loss Anaplastic thyroid cancer
5 99673 16 28082639 28922556 Gain Anaplastic thyroid cancer
6 114238 17 45949240 46466966 Gain Anaplastic thyroid cancer
7 124653 19 11950033 12150103 Gain Anaplastic thyroid cancer
8 128382 19 40542097 41211643 Gain Anaplastic thyroid cancer
9 152529 20 31497814 33184582 Gain Anaplastic thyroid cancer
10 153944 20 41887694 44153298 Gain UBE2C Anaplastic thyroid cancer
11 161614 22 19538297 19939137 Gain Anaplastic thyroid cancer
12 164302 22 36003989 36444264 Gain Anaplastic thyroid cancer
13 171639 3 170900000 182700000 Copy number PIK3CA Anaplastic thyroid cancer
14 182004 4 132076562 133123563 Loss Anaplastic thyroid cancer
15 188265 4 61317501 66095641 Loss Anaplastic thyroid cancer
16 211600 6 33165527 33494594 Gain Anaplastic thyroid cancer
17 225370 7 45400000 54000000 Amplification EGFR Anaplastic thyroid cancer
18 227803 7 72035816 72259198 Gain Anaplastic thyroid cancer

Expression for Thyroid Gland Anaplastic Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Anaplastic Carcinoma.

Pathways for Thyroid Gland Anaplastic Carcinoma

Pathways related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1 13.62 TSHR TP53 RET PTEN PIK3CA CTNNB1
2 12.6 TP53 PTEN PIK3CA CTNNB1 CDH1
3
Show member pathways
12.42 TP53 PTEN PIK3CA CTNNB1 CDH1 BRAF
4
Show member pathways
12.32 TP53 PIK3CA CTNNB1 CDH1 BRAF
5
Show member pathways
12.31 TP53 PTEN PIK3CA CTNNB1 BRAF
6 12.21 BRAF CTNNB1 PIK3CA PTEN
7
Show member pathways
12.14 TP53 PTEN PIK3CA BRAF
8 12.08 TP53 CTNNB1 CDH1 BRAF
9 12.06 TP53 PIK3CA CTNNB1 CDH1
10
Show member pathways
11.86 TP53 PTEN PIK3CA CTNNB1 CDH1 BRAF
11 11.82 TP53 PTEN PIK3CA
12 11.77 TP53 PTEN PIK3CA CTNNB1
13 11.73 TP53 PTEN CTNNB1 CDH1 BRAF
14
Show member pathways
11.72 RET PIK3CA BRAF
15 11.66 PIK3CA CTNNB1 CDH1
16 11.65 TP53 PTEN CTNNB1
17 11.6 PIK3CA CTNNB1 BRAF
18 11.59 TP53 PTEN PIK3CA
19 11.59 TSHR TP53 PIK3CA CTNNB1
20 11.54 TSHR PIK3CA BRAF
21
Show member pathways
11.54 TP53 PTEN PIK3CA
22 11.46 TP53 PTEN CTNNB1
23 11.43 RET CTNNB1 CDH1
24 11.42 TSHR CTNNB1 CDH1
25 11.42 TP53 PTEN PIK3CA CTNNB1
26 11.31 BRAF CDH1 TP53
27
Show member pathways
11.28 PIK3CA CTNNB1 CDH1
28 11.12 PIK3CA CTNNB1 CDH1
29 10.88 TG TPO TSHR
30 10.85 TP53 MIR34C MIR19A MIR18A MIR17
31 10.81 CTNNB1 CDH1
32 10.65 TP53 BRAF
33 10.65 PIK3CA BRAF
34 10.65 TP53 CDH1
35 10.53 RET BRAF

GO Terms for Thyroid Gland Anaplastic Carcinoma

Cellular components related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 8.92 MIR30D MIR30A MIR19A MIR17

Biological processes related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.25 TP53 RET NKX2-1 MIR17 CTNNB1 BRAF
2 negative regulation of gene expression GO:0010629 10.02 TP53 PIK3CA MIR19A MIR17 CTNNB1
3 T cell differentiation in thymus GO:0033077 9.91 TP53 CTNNB1 BRAF
4 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.8 TP53 NKX2-1 MIR18A MIR17
5 endothelial cell migration GO:0043542 9.77 PTEN PIK3CA CALCA
6 cellular response to indole-3-methanol GO:0071681 9.71 CDH1 CTNNB1
7 vasculature development GO:0001944 9.56 PIK3CA CTNNB1 CALCA
8 thyroid gland development GO:0030878 9.56 TG PAX8 NKX2-1 BRAF
9 regulation of axon regeneration GO:0048679 9.49 PTEN BRAF
10 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.46 MIR34C MIR17
11 thyroid-stimulating hormone signaling pathway GO:0038194 9.46 TSHR PAX8
12 negative regulation of sprouting angiogenesis GO:1903671 8.92 MIR34C MIR19A MIR18A MIR17

Molecular functions related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 TP53 MIR34C MIR30D MIR30A MIR19A MIR17
2 thyroid-stimulating hormone receptor activity GO:0004996 9.46 TSHR PAX8
3 mRNA base-pairing translational repressor activity GO:1903231 9.1 MIR34C MIR30D MIR30A MIR19A MIR18A MIR17

Sources for Thyroid Gland Anaplastic Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....